<status value="draft"/> <subjectType value="Patient"/> <date value="2025-03-24"/> <publisher value="Lithuanian Medical Library"/> <contact> <name value="Lithuanian Medical Library"/> <telecom> <system value="url"/> <value value="https://medicinosnk.lt"/> </telecom> <telecom> <system value="email"/> <value value="info@medicinosnk.lt"/> </telecom> </contact> <jurisdiction> <coding> <system value="urn:iso:std:iso:3166"/> <code value="LT"/> </coding> </jurisdiction> <item> <linkId value="grp-specimen"/> <text value="Specimen and macroscopic context"/> <type value="group"/> <item> <linkId value="bioptate-length-mm"/> <text value="Bioptate length (mm)"/> <type value="quantity"/> </item> <item> <linkId value="specimen-quality"/> <text value="Quality of materials"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="specimen-satisfactory"/> <display value="Specimen satisfactory for evaluation"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="specimen-limited"/> <display value="Specimen satisfactory but limited"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="specimen-insufficient"/> <display value="Insufficient tissue for diagnosis"/> </valueCoding> </answerOption> </item> </item> <item> <linkId value="grp-treatment-effect"/> <text value="Treatment effect (selected)"/> <type value="group"/> <item> <linkId value="treatment-effect"/> <text value="Treatment effect on tumour"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="treatment-unknown"/> <display value="Treatment effect unknown"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="treatment-unidentifiable"/> <display value="Treatment effect unidentifiable"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="treatment-radiotherapy"/> <display value="Observed radiotherapy effect"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="treatment-hormone"/> <display value="Observed hormone therapy effect"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="treatment-other"/> <display value="Observed other therapy effect"/> </valueCoding> </answerOption> </item> </item> <item> <linkId value="grp-histology"/> <text value="Histological tumour type"/> <type value="group"/> <item> <linkId value="histological-type"/> <text value="Primary histological type"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-acinar"/> <display value="Acinar adenocarcinoma (conventional)"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-acinar-signet-ring"/> <display value="Acinar adenocarcinoma, signet-ring cell-like"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-acinar-pleomorphic"/> <display value="Acinar adenocarcinoma, pleomorphic giant cell"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-acinar-sarcomatoid"/> <display value="Acinar adenocarcinoma, sarcomatoid"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-acinar-pin-like"/> <display value="Acinar adenocarcinoma, PIN-like"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-idc-isolated"/> <display value="Isolated intraductal carcinoma"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-ductal"/> <display value="Ductal adenocarcinoma"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-adenosquamous"/> <display value="Adenosquamous carcinoma"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-squamous"/> <display value="Squamous cell carcinoma"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-basal-cell"/> <display value="Basal cell (adenoid cystic) carcinoma"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-neuro-adeno"/> <display value="Adenocarcinoma with neuroendocrine differentiation"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-neuro-well-diff"/> <display value="Well-differentiated neuroendocrine tumor"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-neuro-small-cell"/> <display value="Small cell neuroendocrine carcinoma"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-neuro-large-cell"/> <display value="Large cell neuroendocrine carcinoma"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-unassessable"/> <display value="Carcinoma, type unassessable"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="hist-other"/> <display value="Other histological type (see comment)"/> </valueCoding> </answerOption> </item> <item> <linkId value="histological-comment"/> <text value="Histological type comment"/> <type value="text"/> </item> </item> <item> <linkId value="grp-grade"/> <text value="Grade (ISUP)"/> <type value="group"/> <item> <linkId value="isup-grade-group"/> <text value="International Society of Urological Pathology grade group"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="isup-gg1"/> <display value="ISUP Grade Group 1 (Gleason 3+3)"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="isup-gg2"/> <display value="ISUP Grade Group 2 (Gleason 3+4)"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="isup-gg3"/> <display value="ISUP Grade Group 3 (Gleason 4+3)"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="isup-gg4"/> <display value="ISUP Grade Group 4 (Gleason 4+4 or equivalent)"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="isup-gg5"/> <display value="ISUP Grade Group 5 (Gleason 4+5 / 5+4 / 5+5)"/> </valueCoding> </answerOption> </item> </item> <item> <linkId value="grp-idc-cribriform"/> <text value="IDC and cribriform"/> <type value="group"/> <item> <linkId value="idc-status"/> <text value="Intraductal carcinoma (IDC)"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="idc-absent"/> <display value="Intraductal carcinoma not identified"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="idc-present"/> <display value="Intraductal carcinoma identifiable"/> </valueCoding> </answerOption> </item> <item> <linkId value="cribriform-status"/> <text value="Cribriform glands"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="cribriform-na"/> <display value="Cribriform not applicable"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="cribriform-unknown"/> <display value="Cribriform undefined"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="cribriform-present"/> <display value="Cribriform identifiable"/> </valueCoding> </answerOption> </item> </item> <item> <linkId value="grp-additional-grade-burden"/> <text value="Additional grade and tumour burden (subset)"/> <type value="group"/> <item> <linkId value="pattern4-pct-band"/> <text value="Quantity of Pattern 4 (percent band)"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="pattern4-pct-na"/> <display value="Pattern 4 %: not applicable"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="pattern4-pct-lte5"/> <display value="Pattern 4 %: ≤5%"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="pattern4-pct-6-10"/> <display value="Pattern 4 %: 6–10%"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="pattern4-pct-gt40"/> <display value="Pattern 4 %: >40%"/> </valueCoding> </answerOption> </item> <item> <linkId value="tumor-percent-in-biopsy"/> <text value="Tumour percentage in biopsy tissue"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="tumor-pct-lt1"/> <display value="Tumour % in biopsy: <1%"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="tumor-pct-1-5"/> <display value="Tumour % in biopsy: 1–5%"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="tumor-pct-gt90"/> <display value="Tumour % in biopsy: >90%"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="tumor-pct-uneval"/> <display value="Tumour %: cannot be evaluated"/> </valueCoding> </answerOption> </item> </item> <item> <linkId value="grp-invasion"/> <text value="Local invasion (subset)"/> <type value="group"/> <item> <linkId value="periprostatic-fat-invasion"/> <text value="Tumour infiltration in periprostatic adipose tissue"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="periprostatic-unknown"/> <display value="Periprostatic fat invasion: unidentifiable"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="periprostatic-absent"/> <display value="Periprostatic fat invasion: not identified"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="periprostatic-present"/> <display value="Periprostatic fat invasion: present"/> </valueCoding> </answerOption> </item> <item> <linkId value="perineural-invasion"/> <text value="Perineural invasion"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="perineural-absent"/> <display value="Perineural invasion not identified"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="perineural-present"/> <display value="Perineural invasion present"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="perineural-ambiguous"/> <display value="Perineural invasion ambiguous"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="perineural-uneval"/> <display value="Perineural invasion cannot be evaluated"/> </valueCoding> </answerOption> </item> <item> <linkId value="perineural-invasion-notes"/> <text value="Perineural invasion notes"/> <type value="text"/> </item> <item> <linkId value="lymphovascular-invasion"/> <text value="Lymphatic and/or vascular tumour invasion"/> <type value="coding"/> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="lymphovascular-absent"/> <display value="Lymphovascular invasion unidentifiable / not available"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="lymphovascular-present"/> <display value="Lymphovascular invasion identifiable"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="lymphovascular-ambiguous"/> <display value="Lymphovascular invasion ambiguous"/> </valueCoding> </answerOption> <answerOption> <valueCoding> <system value="https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options"/> <code value="lymphovascular-uneval"/> <display value="Lymphovascular invasion cannot be evaluated"/> </valueCoding> </answerOption> </item> <item> <linkId value="lymphovascular-invasion-notes"/> <text value="Lymphovascular invasion notes"/> <type value="text"/> </item> </item> </Questionnaire>

Lithuanian

Generated Narrative: Questionnaire questionnaire-prostate-pathology-espbi

Language: en

Structure

LinkID	Text	Cardinality	Type	Description & Constraints
ProstatePathologyEspbi			Questionnaire	https://hl7.lt/fhir/prostate/Questionnaire/prostate-pathology-espbi#0.1.0
grp-specimen	Specimen and macroscopic context	0..1	group
bioptate-length-mm	Bioptate length (mm)	0..1	quantity
specimen-quality	Quality of materials	0..1	coding	Options: 3 options
grp-treatment-effect	Treatment effect (selected)	0..1	group
treatment-effect	Treatment effect on tumour	0..1	coding	Options: 5 options
grp-histology	Histological tumour type	0..1	group
histological-type	Primary histological type	0..1	coding	Options: 16 options
histological-comment	Histological type comment	0..1	text
grp-grade	Grade (ISUP)	0..1	group
isup-grade-group	International Society of Urological Pathology grade group	0..1	coding	Options: 5 options
grp-idc-cribriform	IDC and cribriform	0..1	group
idc-status	Intraductal carcinoma (IDC)	0..1	coding	Options: 2 options
cribriform-status	Cribriform glands	0..1	coding	Options: 3 options
grp-additional-grade-burden	Additional grade and tumour burden (subset)	0..1	group
pattern4-pct-band	Quantity of Pattern 4 (percent band)	0..1	coding	Options: 4 options
tumor-percent-in-biopsy	Tumour percentage in biopsy tissue	0..1	coding	Options: 4 options
grp-invasion	Local invasion (subset)	0..1	group
periprostatic-fat-invasion	Tumour infiltration in periprostatic adipose tissue	0..1	coding	Options: 3 options
perineural-invasion	Perineural invasion	0..1	coding	Options: 4 options
perineural-invasion-notes	Perineural invasion notes	0..1	text
lymphovascular-invasion	Lymphatic and/or vascular tumour invasion	0..1	coding	Options: 4 options
lymphovascular-invasion-notes	Lymphovascular invasion notes	0..1	text
Documentation for this format

Options Sets

Answer options for specimen-quality

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#specimen-satisfactory ("Specimen satisfactory for evaluation")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#specimen-limited ("Specimen satisfactory but limited")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#specimen-insufficient ("Insufficient tissue for diagnosis")

Answer options for treatment-effect

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-unknown ("Treatment effect unknown")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-unidentifiable ("Treatment effect unidentifiable")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-radiotherapy ("Observed radiotherapy effect")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-hormone ("Observed hormone therapy effect")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#treatment-other ("Observed other therapy effect")

Answer options for histological-type

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar ("Acinar adenocarcinoma (conventional)")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-signet-ring ("Acinar adenocarcinoma, signet-ring cell-like")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-pleomorphic ("Acinar adenocarcinoma, pleomorphic giant cell")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-sarcomatoid ("Acinar adenocarcinoma, sarcomatoid")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-acinar-pin-like ("Acinar adenocarcinoma, PIN-like")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-idc-isolated ("Isolated intraductal carcinoma")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-ductal ("Ductal adenocarcinoma")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-adenosquamous ("Adenosquamous carcinoma")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-squamous ("Squamous cell carcinoma")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-basal-cell ("Basal cell (adenoid cystic) carcinoma")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-adeno ("Adenocarcinoma with neuroendocrine differentiation")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-well-diff ("Well-differentiated neuroendocrine tumor")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-small-cell ("Small cell neuroendocrine carcinoma")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-neuro-large-cell ("Large cell neuroendocrine carcinoma")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-unassessable ("Carcinoma, type unassessable")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#hist-other ("Other histological type (see comment)")

Answer options for isup-grade-group

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg1 ("ISUP Grade Group 1 (Gleason 3+3)")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg2 ("ISUP Grade Group 2 (Gleason 3+4)")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg3 ("ISUP Grade Group 3 (Gleason 4+3)")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg4 ("ISUP Grade Group 4 (Gleason 4+4 or equivalent)")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#isup-gg5 ("ISUP Grade Group 5 (Gleason 4+5 / 5+4 / 5+5)")

Answer options for idc-status

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#idc-absent ("Intraductal carcinoma not identified")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#idc-present ("Intraductal carcinoma identifiable")

Answer options for cribriform-status

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#cribriform-na ("Cribriform not applicable")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#cribriform-unknown ("Cribriform undefined")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#cribriform-present ("Cribriform identifiable")

Answer options for pattern4-pct-band

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-na ("Pattern 4 %: not applicable")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-lte5 ("Pattern 4 %: ≤5%")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-6-10 ("Pattern 4 %: 6–10%")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#pattern4-pct-gt40 ("Pattern 4 %: >40%")

Answer options for tumor-percent-in-biopsy

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-lt1 ("Tumour % in biopsy: <1%")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-1-5 ("Tumour % in biopsy: 1–5%")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-gt90 ("Tumour % in biopsy: >90%")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#tumor-pct-uneval ("Tumour %: cannot be evaluated")

Answer options for periprostatic-fat-invasion

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#periprostatic-unknown ("Periprostatic fat invasion: unidentifiable")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#periprostatic-absent ("Periprostatic fat invasion: not identified")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#periprostatic-present ("Periprostatic fat invasion: present")

Answer options for perineural-invasion

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-absent ("Perineural invasion not identified")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-present ("Perineural invasion present")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-ambiguous ("Perineural invasion ambiguous")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#perineural-uneval ("Perineural invasion cannot be evaluated")

Answer options for lymphovascular-invasion

https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-absent ("Lymphovascular invasion unidentifiable / not available")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-present ("Lymphovascular invasion identifiable")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-ambiguous ("Lymphovascular invasion ambiguous")
https://tx.hl7.lt/fhir/CodeSystem/prostate-questionnaire-options#lymphovascular-uneval ("Lymphovascular invasion cannot be evaluated")